Kitonail (Ciclopirox)

Ciclopirox, the active ingredient in Kitonail, is an antifungal presented as a nail lacquer (strength not specified) for topical use. It treats fungal nail infections such as onychomycosis in adults. GNH USA supplies Kitonail as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ciclopirox is used to treat fungal infections of the nail and skin.

Onychomycosis: reduces fungal growth and promotes clearance of infected nails. Dermatophytosis: eliminates skin‑surface fungi causing conditions such as athlete's foot and ringworm.

Ciclopirox may cause local and systemic adverse reactions.

Common Side Effects: - Application site irritation: mild redness or discomfort where applied. - Pruritus: itching of the treated area. - Dryness or peeling of the nail surface. - Burning sensation during or after application. - Discoloration of the nail plate. - Erythema: localized skin redness.

Serious or Rare Side Effects: - Allergic contact dermatitis: severe skin reaction with swelling and blisters. - Systemic hypersensitivity: rare systemic allergic response such as urticaria. - Severe skin reaction: Stevens‑Johnson syndrome or toxic epidermal necrolysis (extremely rare). - Hepatic toxicity: rare liver enzyme elevation reported with extensive use.

Ciclopirox should be used with attention to specific safety considerations.

Pregnancy: safety not established; use only if clearly needed. Breastfeeding: unknown safety profile; exercise caution. Renal impairment: no dosage adjustment required, but monitor renal function. Use only on intact nails and surrounding skin; avoid application to broken skin. Avoid extensive use on large skin areas to reduce irritation risk. Store at room temperature: keep in original packaging, protect from moisture and direct light.

Ciclopirox may interact with other medications, requiring attention to potential effects.

Major Interactions (Avoid): - Concurrent topical antifungals: may increase local irritation. - Systemic antifungal agents (e.g., itraconazole): additive toxicity risk.

Moderate Interactions (Monitor Closely): - Co‑administration with corticosteroid creams: may mask infection signs. - Use with photosensitizing agents: heightened sun sensitivity. - Interaction with other chelating agents: possible reduction in antifungal efficacy.